Physician
Nordfeldt, Rocio
Nordfeldt, Rocio was paid $47K by Medicaid between Jan 2018 and Dec 2024, across 14 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 44% of everything it billed.
33Billing provider infoNORDFELDT, ROCIO
MARLBOROUGH, MA 01752
MARLBOROUGH, MA 01752
33aNPI1043530033assigned 06/02/2010
33bProvider typeFamily Medicine Physician
28Total paid$47K
24GClaims3,116
24DCodes billed14
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Massachusetts
Rank by total paid#234 of 744
Median peer was paid$10K
This provider vs. median4.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 593 | $38K | |
| 2023 | 1,232 | $5K | |
| 2024incomplete | 1,291 | $4K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 44% | 665 | 518 | $21K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 29% | 282 | 101 | $13K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 12% | 541 | 537 | $6K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.4% | 747 | 698 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.8% | 22 | 15 | $1K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.4% | 335 | 333 | $665.76 |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.2% | 110 | 110 | $547.12 |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 104 | 104 | $415.75 |
| 90461 | <1% | 121 | 121 | $285.36 | |
| 90688 | <1% | 14 | 14 | $263.90 | |
| 90658 | <1% | 15 | 15 | $170.55 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 122 | 122 | $20.45 |
2 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.